Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, Missouri 63110, United States.
J Am Soc Mass Spectrom. 2023 Nov 1;34(11):2508-2517. doi: 10.1021/jasms.3c00223. Epub 2023 Oct 18.
Histones are DNA binding proteins that allow for packaging of the DNA into the nucleus. They are abundantly present across the genome and thus serve as a major site of epigenetic regulation through the use of post-translational modifications (PTMs). Aberrations in histone expression and modifications have been implicated in a variety of human diseases and thus are a major focus of disease etiology studies. A well-established method for studying histones and PTMs is through the chemical derivatization of isolated histones followed by liquid chromatography and mass spectrometry analysis. Using such an approach has allowed for a swath of discoveries to be found, leading to novel therapeutics such as histone deacetylase (HDAC) inhibitors that have already been applied in the clinic. However, with the rapid improvement in instrumentation and data analysis pipelines, it remains important to temporally re-evaluate the established protocols to improve throughput and ensure data quality. Here, we optimized the histone derivatization procedure to increase sample throughput without compromising peptide quantification. An implemented spike-in standard peptide further serves as a quality control to evaluate the propionylation and digestion efficiencies as well as reproducibility in chromatographic retention and separation. Last, the application of various data-independent acquisition (DIA) strategies was explored to ensure low variation between runs. The output of this study is a newly optimized derivatization protocol and mass spectrometry method that maintains high identification and quantification of histone PTMs while increasing sample throughput.
组蛋白是一种与 DNA 结合的蛋白质,它可以将 DNA 包装到细胞核内。组蛋白在基因组中大量存在,因此可以通过翻译后修饰(PTMs)成为表观遗传调控的主要位点。组蛋白表达和修饰的异常与多种人类疾病有关,因此是疾病病因学研究的重点。研究组蛋白和 PTMs 的一种成熟方法是通过分离组蛋白的化学衍生化,然后进行液相色谱和质谱分析。采用这种方法已经发现了大量的发现,导致了新型治疗方法的出现,如组蛋白去乙酰化酶(HDAC)抑制剂,已经在临床上得到应用。然而,随着仪器和数据分析管道的快速改进,仍然有必要定期重新评估既定的方案,以提高通量并确保数据质量。在这里,我们优化了组蛋白衍生化程序,在不影响肽定量的情况下提高了样品通量。实施的内标肽进一步作为质量控制,以评估丙酰化和消化效率以及色谱保留和分离的重现性。最后,还探索了各种数据非依赖性采集(DIA)策略的应用,以确保运行之间的低变化。本研究的结果是一个新的优化的衍生化方案和质谱方法,在提高样品通量的同时保持了组蛋白 PTM 的高鉴定和定量。